![Mathias Locher](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Profiel
Mathias Locher is currently the Chief Development Officer at Covagen AG.
Previously, he held the position of Vice President-PreClinical Development at Micromet AG.
From 2007 to 2011, he worked at Merck Serono SA as the Global Head-Drug Metabolism & Pharmacokinetics.
He also served as the Chief Development Officer at Heidelberg Pharma AG from 2021 to 2023.
Dr. Locher obtained a doctorate degree from Eberhard Karls Universität Tübingen.
Eerdere bekende functies van Mathias Locher
| Bedrijven | Functie | Einde |
|---|---|---|
| HEIDELBERG PHARMA AG | Corporate Officer/Principal | 01-04-2023 |
Covagen AG
 Covagen AG BiotechnologyHealth Technology Develops next generation protein drugs for the treatment of inflammatory diseases and cancer | Corporate Officer/Principal | 04-06-2020 |
Merck Serono SA
 Merck Serono SA Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company that develops drugs for reproductive and metabolism | Corporate Officer/Principal | 01-01-2011 |
Micromet AG
 Micromet AG Pharmaceuticals: MajorHealth Technology Manufactures and markets drugs | Corporate Officer/Principal | - |
Opleiding van Mathias Locher
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
10
Eerstegraads connecties
5
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 5 |
|---|---|
Micromet AG
Micromet AG Pharmaceuticals: MajorHealth Technology Manufactures and markets drugs | Health Technology |
Heidelberg Pharma AG
 Heidelberg Pharma AG Pharmaceuticals: MajorHealth Technology Develops cancer therapies | Health Technology |
Eberhard Karls Universität Tübingen
 Eberhard Karls Universität Tübingen Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Merck Serono SA
Merck Serono SA Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company that develops drugs for reproductive and metabolism | Health Technology |
Covagen AG
Covagen AG BiotechnologyHealth Technology Develops next generation protein drugs for the treatment of inflammatory diseases and cancer | Health Technology |
